Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 07 - 08

Efung News | HighLight Pharma’s Genoxitenib (TLL-018) Receives CDE Breakthrough Therapy Designation

HighLight Pharma today announced that its independently developed oral, highly selective JAK1/TYK2 dual inhibitor, Genoxitenib (TLL-018), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis (RA).This designation is based on positive topline data from the Phase III registrational study (TARA) of Genoxitenib. The CDE, following its review, determined that Genoxitenib meets the eligibility criteria for Breakthrough Therapy Designation, as it is intended to p...

浏览次数：2

查看详情>>

发布时间: 2026 - 07 - 05

EFUNG NEWS | New Potential in Tumor Immunology! Symposium on Azvudine's Novel Mechanisms and Clinica

On July 2, the "Symposium on Azvudine's Novel Mechanisms and Clinical Translation," hosted by the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences, was held in Beijing. At the conference, Jiang Jiandong, Academician of the Chinese Academy of Engineering and Dean of the Institute of Materia Medica at the Chinese Academy of Medical Sciences, reported that four years after azvudine's market launch, his team has continued to conduct in-depth research into the drug's new mechanisms. The latest study published in June suggests that azvudine, as th...

浏览次数：2

查看详情>>

发布时间: 2026 - 07 - 04

EFUNG HONOR | Zhu Pai of Efung Capital Named to [Entrepreneur] 2026 Young Venture Capital List

Young investors are not just hunting for the next unicorn—they are incubating the future of a technologically powerful nation.Today, [Entrepreneur] officially unveiled its 2026 Young Venture Capital List. Zhu Pai, CEO of Efung Capital, has been named to the "Under 40 Investors" ranking, solidifying his position as a key driving force in the current wave of young venture capital.Entrepreneur has long focused on the young venture capital community. Since 2013, it has held the "Under 40 Investors" selection for 14 consecutive years, aiming to identify capital visionaries who a...

浏览次数：4

查看详情>>

发布时间: 2026 - 07 - 01

Efung News | National Major New Drug Creation Special Project Support! Omer Pharmaceutic

On July 1, the NMPA official website announced that Omecamson (Agluconate Sodium Injection), a Class 1 new drug jointly filed by Omer Pharmaceutical and Xianju Pharmaceutical, has been approved for marketing in China.Notably, this drug is the only targeted muscle relaxant antagonist in China and one of only two worldwide. Upon approval, it has also become the only patent-protected drug in the muscle relaxant antagonism field globally.Screenshot from NMPA official websiteOmecamson:Making "Awakening" Safer and More ControllableMuscle relaxation is one of the three essential elements of...

浏览次数：7

查看详情>>